531. GM-1020 is a Novel, Orally Bioavailable NMDA Antagonist With Improved Separation Between Antidepressant and Ataxic Doses Compared to Ketamine

Since initial demonstration of rapid antidepressant efficacy with (R,S)-Ketamine, S-Ketamine has been approved for treatment-resistant depression. Clinical use of ketamine is limited by poor bioavailability and dissociative side effects. The novel NMDA antagonist GM-1020 was designed to address these shortcomings.